An update of " Cost-effectiveness of rotavirus vaccination in the Netherlands: The results of a Consensus Rotavirus Vaccine model"

BMC Infectious Diseases

Volumn 13, Issue 1, 2013, Pages

  Tu, Hong Anh T ^a   Rozenbaum, Mark H ^a   de Boer, Pieter T ^a   Noort, Albert C ^a   Postma, Maarten J ^a  

^a UNIVERSITY OF TORONTO   (Canada)

Author keywords

Cost effectiveness analysis; Rotavirus vaccination; The Netherlands

Indexed keywords

ROTAVIRUS VACCINE;

ADULT; ARTICLE; CHILD; CLINICAL DECISION MAKING; CONSENSUS DEVELOPMENT; COST EFFECTIVENESS ANALYSIS; DRUG COST; EVIDENCE BASED MEDICINE; HEALTH CARE COST; HEALTH PROGRAM; HERD IMMUNITY; HOSPITAL INFECTION; HUMAN; INCIDENCE; INFECTION PREVENTION; NETHERLANDS; QUALITY ADJUSTED LIFE YEAR; ROTAVIRUS INFECTION; VACCINATION; VIRUS TRANSMISSION;

COST-BENEFIT ANALYSIS; GASTROENTERITIS; HOSPITALIZATION; HUMANS; NETHERLANDS; QUALITY-ADJUSTED LIFE YEARS; ROTAVIRUS; ROTAVIRUS INFECTIONS; ROTAVIRUS VACCINES; VACCINATION;

EID: 84873037895     PISSN: None     EISSN: 14712334     Source Type: Journal    
DOI: 10.1186/1471-2334-13-54     Document Type: Article

References (21)

1. Rozenbaum MH, Mangen MJ, Giaquinto C, Wilschut JC, Hak E, Postma MJ. Cost-effectiveness of rotavirus vaccination in the Netherlands; the results of a consensus model. BMC Public Health 2011, 11:462. 10.1186/1471-2458-11-462, 3129591, 21663620.
2. Bruijning-Verhagen P, de Waal W, Winkel L, Felderhof M, van Houten M, Thijsen S, et al. Rotavirus related hospitalizations: Incidence and contribution to seasonal peaks in pediatric hospital admissions 2012, Thessaloniki, Greece: Poster at ESPID-conference 2012.
3. Friesema IH, De Boer RF, Duizer E, Kortbeek LM, Notermans DW, Norbruis OF, et al. Etiology of acute gastroenteritis in children requiring hospitalization in the Netherlands. Eur J Clin Microbiol Infect Dis 2012, 31:405-415. 10.1007/s10096-011-1320-0, 21725865.
4. de Wit MA, Koopmans MP, Kortbeek LM, van Leeuwen NJ, Bartelds AI, van Duynhoven YT. Gastroenteritis in sentinel general practices, The Netherlands. Emerg Infect Dis 2001, 7:82-91. 10.3201/eid0701.010113, 2631671, 11266298.
5. de Wit MA, Koopmans MP, Kortbeek LM, Wannet WJ, Vinje J, van LF, et al. Sensor, a population-based cohort study on gastroenteritis in the Netherlands: incidence and etiology. Am J Epidemiol 2001, 154:666-674. 10.1093/aje/154.7.666, 11581101.
6. Mangen MJ, van Duynhoven YT, Vennema H, Van PW, Havelaar AH, de Melker HE. Is it cost-effective to introduce rotavirus vaccination in the Dutch national immunization program?. Vaccine 2010, 28:2624-2635. 10.1016/j.vaccine.2010.01.014, 20109593.
7. Zomer TP, van Duynhoven YT, Mangen MJ, van der Maas NA, Vennema H, Boot H, et al. Assessing the introduction of universal rotavirus vaccination in the Netherlands. Vaccine 2008, 26:3757-3764. 10.1016/j.vaccine.2008.04.039, 18514975.
8. Glass RI. Unexpected benefits of rotavirus vaccination in the United States. J Infect Dis 2011, 204:975-977. 10.1093/infdis/jir477, 21878426.
9. de Wit MA, Koopmans MP, van der Blij JF, van Duynhoven YT. Hospital admissions for rotavirus infection in the Netherlands. Clin Infect Dis 2000, 31:698-704. 10.1086/314025, 11017818.
10. Goossens LM, Standaert B, Hartwig N, Hovels AM, Al MJ. The cost-utility of rotavirus vaccination with Rotarix (RIX4414) in the Netherlands. Vaccine 2008, 26:1118-1127. 10.1016/j.vaccine.2007.11.070, 18215445.
11. Jit M, Bilcke J, Mangen MJ, Salo H, Melliez H, Edmunds WJ, et al. The cost-effectiveness of rotavirus vaccination: comparative analyses for five European countries and transferability in Europe. Vaccine 2009, 27:6121-6128. 10.1016/j.vaccine.2009.08.030, 19715781.
12. Lopman BA, Curns AT, Yen C, Parashar UD. Infant rotavirus vaccination may provide indirect protection to older children and adults in the United States. J Infect Dis 2011, 204:980-986. 10.1093/infdis/jir492, 21878425.
13. Atkins KE, Shim E, Pitzer VE, Galvani AP. Impact of rotavirus vaccination on epidemiological dynamics in England and Wales. Vaccine 2012, 30:552-564. 10.1016/j.vaccine.2011.11.064, 22133508.
14. Van ET, Soriano-Gabarro M, Debrus S, Claire NE, Gray J. A mathematical model of the indirect effects of rotavirus vaccination. Epidemiol Infect 2010, 138:884-897. 10.1017/S0950268809991245, 20028612.
15. Buttery JP, Lambert SB, Grimwood K, Nissen MD, Field EJ, Macartney KK, et al. Reduction in rotavirus-associated acute gastroenteritis following introduction of rotavirus vaccine into Australia's National Childhood vaccine schedule. Pediatr Infect Dis J 2011, 30:S25-S29.
16. Chang HG, Smith PF, Tserenpuntsag B, Markey K, Parashar U, Morse DL. Reduction in hospitalizations for diarrhea and rotavirus infections in New York state following introduction of rotavirus vaccine. Vaccine 2010, 28:754-758. 10.1016/j.vaccine.2009.10.075, 19896451.
17. Curns AT, Steiner CA, Barrett M, Hunter K, Wilson E, Parashar UD. Reduction in acute gastroenteritis hospitalizations among US children after introduction of rotavirus vaccine: analysis of hospital discharge data from 18 US states. J Infect Dis 2010, 201:1617-1624. 10.1086/652403, 20402596.
18. Lambert SB, Faux CE, Hall L, Birrell FA, Peterson KV, Selvey CE, et al. Early evidence for direct and indirect effects of the infant rotavirus vaccine program in Queensland. Med J Aust 2009, 191:157-160.
19. Paulke-Korinek M, Kundi M, Rendi-Wagner P, de MA, Eder G, Schmidle-Loss B, et al. Herd immunity after two years of the universal mass vaccination program against rotavirus gastroenteritis in Austria. Vaccine 2011, 29:2791-2796. 10.1016/j.vaccine.2011.01.104, 21320539.
20. Payne DC, Staat MA, Edwards KM, Szilagyi PG, Weinberg GA, Hall CB, et al. Direct and indirect effects of rotavirus vaccination upon childhood hospitalizations in 3 US Counties, 2006-2009. Clin Infect Dis 2011, 53:245-253. 10.1093/cid/cir307, 21705316.
21. Parashar UD, Alexander JP, Glass RI. Prevention of rotavirus gastroenteritis among infants and children. Recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep 2006, 55:1-13.